| Heading: |
Sipavibart: Licensing |
| Question ID: |
1751334 |
| UIN: |
21239 |
| House: |
Commons |
| Date tabled: |
2024-12-18 |
| Asking Member ID: |
5283 |
| Asking Member display name: |
Alison Bennett
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Alison Bennett
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, whether he has had discussions with the National Institute for Health and Care Excellence on the licensing process for the drug sipavibart. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-01-06 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
Department officials regularly discuss a range of topics with the National Institute for Health and Care Excellence (NICE), including progress with specific appraisals, such as for sipavibart.The NICE started its appraisal of the medicine sipavibart for p... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |